CASI gets nod to extend U.S. PhII on ENMD-2076 into China


China-Focused and Nasdaq-listed CASI Pharmaceuticals ($CASI) has won China FDA approval to extend a U.S. Phase II clinical trial into China for its candidate ENMD-2076 aimed at fibrolamellar carcinoma.

The candidate is currently the focus of three Phase II trials in China and the U.S. for other indications for the oral Aurora A/angiogenic kinase inhibitor.

"We are pleased with CFDA's approval of our application to expand the ongoing Phase II trial for FLC into China," Ken K. Ren, CEO, said in a statement.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"This is our fourth approval from CFDA to conduct Phase II trials with our novel and orally-active Aurora A/angiogenic kinase inhibitor, and confirms our core competency to navigate and obtain CFDA approvals to conduct trials in China as part of a global clinical program."

The candidate has already received U.S. FDA orphan drug designations covering ovarian, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma--as well as a similar EMA designation on hepatocellular carcinoma.

The development of the drug is in addition to ongoing licensing efforts by CASI in oncology in China. In January, CASI won a China FDA nod for oncology therapy Marqbio licensed for China rights from Spectrum Pharmaceuticals ($SPPI) in a 2014 deal covering two oncology therapies.

The company plans a confirmatory trial in China for the spectrum candidate in China, part of a growing clinical profile that was aided by raising $25 million in a secondary offering last year earmarked for clinical trials.

- here's the release from CASI


Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.